ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 859

Endothelin-1 (ET-1) Induces Extracellular Matrix Protein Production by Human Temporal Artery Derived Myointimal Cells. A Mechanism Potentially Leading to Intimal Hyperplasia and Vascular Occlusion in Giant-Cell Arteritis

Ester Planas-Rigol1, Marc Corbera-Bellalta2, Marco A. Alba3, Itziar Tabera-Bahillo3, Sergio Prieto-Gonzalez3, Georgina espigol-Frigole3, Jose Hernandez-Rodriguez4, Ester Lozano5 and Maria C. Cid6, 1Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Hospital Clinic University Barcelona, Hospital Clinic University Barcelona, Barcelona, Spain, 3Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clinic University Barcelona, Barcelona, Spain, 4Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 5Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clinic University Barcelona, 6Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: extracellular matrix proteins, giant cell arteritis, inflammation and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Endothelin-1 (ET-1) is the main isoform of the Endothelin family. It is also the most powerful vasoconstrictor identified. ET-1 is constitutively produced in blood vessels by endothelial cells and vascular smooth muscle cells (VSMC). VSMC express two endothelin receptors: Endothelin receptor A and B (ETAR and ETBR) but the main effect of vasoconstriction may be the result of the interaction between ET-1 and ETAR. Transforming Growth Factor β1 is a fibrogenic cytokine and recent studies suggest that ET-1 contributes to the fibrogenic effect of TGFβ by fibroblasts.

To investigate whether ET-1 and TGFβ may contribute to vascular occlusion by inducing pro-fibrotic responses in cultured vascular myointimal cells

Methods:

VSMC were obtained from cultured human temporal artery sections obtained for diagnostic purposes as described (Ann Rheum Dis. 2008 Nov; 67(11):1581-8). ET-1, TGFb, collagen type I (COL1) and type III (COL3) expression was assessed by quantitative real-time PCR (TaqmanR Gene Expression Assay) from Applied Biosystems. COL1 and COL3 protein production was determined by ELISA (Takara and USNC Biological) kits respectively.

Results:

ET-1 and TGFb up regulated COL1, COL3 expression by VSMC at the mRNA and protein level. This increase was inhibited by ETAR receptor antagonist BQ123 and partially abrogated by ALK5 inhibitor SB525334.

ET-1 induced indeed a remarkable early expression of TGFβ and TGFb induced, in turn, a later induction of ET-1. A double blockade of these cytokines enhanced the inhibition of COL1 and COL3 expression suggesting that collagen production by VSMC may be dependent of both ET-1 and TGFβ.

Phenotypic changes in ET-1-treated-VSMC were also observed. These cells became adherent earlier than untreated ones. Treatment with BQ123 reverted this phenotype suggesting that ET-1 may have an important role in the regulation of VSMC adhesion and migration

Conclusion:

ET-1 may contribute to intimal hyperplasia directly by inducing collagen type I and III by human medium-size artery derived myointimal cells. Since ET-1 and TGFb are expressed in GCA lesions these preliminary results suggest that ETAR and ALK5 receptor antagonists may prevent intimal hyperplasia and vascular occlusion in GCA.

Supported by SAF 08/04328 and SAF 11/30073


Disclosure:

E. Planas-Rigol,
None;

M. Corbera-Bellalta,
None;

M. A. Alba,
None;

I. Tabera-Bahillo,
None;

S. Prieto-Gonzalez,
None;

G. espigol-Frigole,
None;

J. Hernandez-Rodriguez,
None;

E. Lozano,
None;

M. C. Cid,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endothelin-1-et-1-induces-extracellular-matrix-protein-production-by-human-temporal-artery-derived-myointimal-cells-a-mechanism-potentially-leading-to-intimal-hyperplasia-and-vascular-occlusion-in/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology